EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study

Yu-Sung Chang, Chieh-Yu Liu, Yu-Wen Chen, Sheng-Hsuan Huang, Hsing-Yu Lin, Chien-Chin Lin, Xavier Cheng-Hong Tsai, Feng-Ming Tien, Chieh-Lung Cheng, Chang-Tsu Yuan, Yuan-Yeh Kuo, Bor-Sheng Ko und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025-12 · 25 (12) · 885-896

DOI: 10.1016/j.clml.2025.06.011 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-12. Verfasst von Yu-Sung Chang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Interferon alpha-2, Polyethylene Glycols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Taiwan University Hospital, Ministry of Science and Technology, Taiwan, Taiwan Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ropeginterferon alfa-2b-njft (ropegIFN) has demonstrated superior efficacy over hydroxyurea in polycythemia vera (PV); however, real-world data on its application across Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) remain limited. PATIENTS AND METHODS: This retrospective cohort study included 64 patients with Ph- MPNs (15 PV, 16 essential thrombocythemia [ET], 5 prefibrotic myelofibrosis [preMF], and 28 with overt myelofibrosis [MF]) treated with ropegIFN between October 2018 and June 2024. RESULTS: After a median follow-up of 5.3 years, the hematological response (HR) rates at 36 months were 87% in PV, 75% in ET, 80% in preMF, and 45% in overt MF (P = .026). Best molecular response (MR) rates were 80% in PV, 69% in ET, 75% in preMF, and 47% in overt MF (P = .11). The median JAK2 variant allele frequency (VAF) declined significantly from 67.9% at baseline to 18.7% during follow-up (P < .001), with consistent reductions across MPN subtypes confirmed by GEE analysis. In patients with MF, neither HR nor MR was observed among those harboring high-molecular-risk (HMR) mutations (24-month HR: 0% vs. 72%; P = .002; 24-month MR: 0% vs. 18%; P = .4). Additionally, these patients exhibited a significantly higher cumulative incidence of adverse events (48% vs. 7%; P < .001). CONCLUSIONS: RopegIFN demonstrated hematological and molecular efficacy across Ph- MPN subtypes and was generally well tolerated. However, its effectiveness appears limited in patients with MF, particularly those with high-molecular-risk (HMR) mutations. These findings support the potential disease-modifying role of ropegIFN and highlight the need for prospective multicenter studies to validate its long-term impact on disease progression and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersInterferon alpha-2Polyethylene GlycolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedRecombinant ProteinsAdultTreatment OutcomeAged, 80 and overInterferon-alpha

Stichwörter der Autor:innen

Essential thrombocythemiaInterferonMyelofibrosisPolycythemia veraPrefibrotic primary myelofibrosis

Substanzen

Interferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsInterferon-alpha

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.

Förderung

  • National Taiwan University Hospital
  • Ministry of Science and Technology, Taiwan
  • Taiwan Ministry of Health and Welfare
  • Taiwan Ministry of Science and Technology

Zitieren

APA

Chang, Y. S., Liu, C. Y., Chen, Y. W., Huang, S. H., Lin, H. Y., Lin, C. C., Tsai, X. C., Tien, F. M., Cheng, C. L., Yuan, C. T., Kuo, Y. Y., Ko, B. S., Yao, M., Tien, H. F., Chou, W. C., & Hou, H. A. (2025). Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia, 25(12), 885-896. https://doi.org/10.1016/j.clml.2025.06.011

Vancouver

Chang YS, Liu CY, Chen YW, Huang SH, Lin HY, Lin CC, et al. Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia. 2025;25(12):885-896. doi:10.1016/j.clml.2025.06.011

BibTeX
@article{Chang2025,
  author = {Chang, Yu-Sung and Liu, Chieh-Yu and Chen, Yu-Wen and Huang, Sheng-Hsuan and Lin, Hsing-Yu and Lin, Chien-Chin and Tsai, Xavier Cheng-Hong and Tien, Feng-Ming and Cheng, Chieh-Lung and Yuan, Chang-Tsu and Kuo, Yuan-Yeh and Ko, Bor-Sheng and Yao, Ming and Tien, Hwei-Fang and Chou, Wen-Chien and Hou, Hsin-An},
  title = {Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  volume = {25},
  number = {12},
  pages = {885--896},
  doi = {10.1016/j.clml.2025.06.011}
}
Kostenlos starten →